CORRESP Filing
AIxCrypto Holdings, Inc.
Date: Sept. 23, 2025 · CIK: 0001460702 · Accession: 0001493152-25-014622
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290306
Letter
Via EDGAR Division of Corporation Finance Office of Life Sciences Attention: Mr. Tyler Howes Registration Statement on Form S-1 Filed September 16, 2025 File No. 333-290306 Request for Acceleration of Effectiveness
Dear Mr. Howes:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the " Registrant ") hereby respectfully requests the U.S. Securities and Exchange Commission (the " Commission ") to accelerate the effectiveness of its Registration Statement on Form S-1 (File No. 333-290306) (the " Registration Statement ") to 4:00 p.m. (Eastern Time) on Friday, September 26, 2025, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission.
Please orally confirm the effectiveness of the Registration Statement with Ross Carmel, Esq. of Sichenzia Ross Ference Carmel LLP, counsel to the Company, at (646) 838-1310.
Very
truly yours,
QUALIGEN THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, CA 92008 September 23, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Tyler Howes Re: Qualigen Therapeutics, Inc. Registration Statement on Form S-1 Filed September 16, 2025 File No. 333-290306 Request for Acceleration of Effectiveness Dear Mr. Howes: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the " Registrant ") hereby respectfully requests the U.S. Securities and Exchange Commission (the " Commission ") to accelerate the effectiveness of its Registration Statement on Form S-1 (File No. 333-290306) (the " Registration Statement ") to 4:00 p.m. (Eastern Time) on Friday, September 26, 2025, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. Please orally confirm the effectiveness of the Registration Statement with Ross Carmel, Esq. of Sichenzia Ross Ference Carmel LLP, counsel to the Company, at (646) 838-1310. Very truly yours, QUALIGEN THERAPEUTICS, INC. By: /s/ Kevin Richardson II Name: Kevin Richardson II Title: Interim Chief Executive Officer cc: Ross Carmel, Esq., Sichenzia Ross Ference Carmel LLP